How Bacteriophages Hijack Bacterial Signaling to Secure Their Own Survival

-

For many years, the relationship between bacteriophages and bacteria was largely viewed as a straightforward arms race in which viruses infect bacterial cells while hosts evolve increasingly sophisticated defense systems to resist invasion. Recent discoveries, however, reveal a far more intricate biological dialogue. Viruses are not merely passive invaders that exploit cellular machinery. They are capable of rewiring bacterial signaling pathways, manipulating intracellular messengers and reshaping regulatory networks to favor their own persistence. A striking example of this remarkable strategy has now been uncovered in Acinetobacter baumannii, one of the most problematic multidrug resistant pathogens encountered in modern hospitals.

© The Phage Therapy

Researchers have discovered that this bacterium naturally produces a class of signaling molecules known as 2′,3′ cyclic nucleotide monophosphates, or 2′,3′ cNMPs. Although related compounds have been extensively studied in plants, mammals and several bacterial species, their role in bacteriophage biology remained largely unexplored. This work reveals that these molecules are not simply metabolic byproducts. Instead, they function as genuine intracellular messengers that influence bacterial physiology, virulence and surprisingly, the ability of bacteriophages to integrate their own DNA into the host genome.

The production of these signaling molecules originates from a ribonuclease called RnaA. By degrading intracellular RNA, this enzyme generates several cyclic nucleotides including 2′,3′ cAMP, 2′,3′ cGMP, 2′,3′ cCMP and 2′,3′ cUMP. Their concentrations are then tightly controlled by phosphodiesterases that degrade these molecules and maintain cellular homeostasis. When researchers removed the rnaA gene, the bacterium completely lost its ability to produce these cyclic nucleotides. This deficiency had profound consequences, significantly reducing biofilm formation and decreasing cytotoxicity toward human lung cells, highlighting the essential role of these molecules in bacterial physiology.

The study then uncovered the molecular sensor responsible for detecting these signaling molecules. A transcription factor called CRPAb acts as a highly specific receptor for 2′,3′ cNMPs, particularly for 2′,3′ cAMP. Unlike classical bacterial CRP proteins, which usually recognize the well known messenger 3′,5′ cAMP, CRPAb has evolved a distinct specificity. Structural analyses demonstrated that subtle modifications within its nucleotide binding domain allow it to selectively recognize 2′,3′ cyclic nucleotides while excluding the classical signaling molecules used by many bacteria.

Once activated by these messengers, CRPAb directly binds to the promoters of several target genes involved in biofilm formation, virulence and prophage biology. The binding affinity of CRPAb to DNA is substantially enhanced by the presence of 2′,3′ cNMPs, effectively transforming these small metabolites into regulatory switches capable of controlling major cellular functions.

The most fascinating aspect of this discovery emerges during bacteriophage infection. When Acinetobacter baumannii is infected by lysogenic phages, intracellular levels of 2′,3′ cNMPs rise dramatically. Rather than increasing their synthesis, phages adopt a more subtle strategy. Viral proteins suppress the expression of bacterial phosphodiesterases responsible for degrading these signaling molecules, allowing cyclic nucleotide concentrations to accumulate inside the cell.

Among these viral regulators, a repressor protein encoded by the phage PhabP_R1 plays a central role. This protein directly inhibits the bacterial gene A1S_0249, one of the principal enzymes involved in 2′,3′ cNMP degradation. As a consequence, signaling molecules accumulate and strongly activate the CRPAb regulatory pathway.

This molecular manipulation produces a remarkable outcome. Elevated levels of 2′,3′ cNMPs stimulate the expression of prophage associated proteins and genes involved in DNA integration. In particular, a prophage protein named A1S_1154 becomes a key downstream regulator. Its activity promotes the expression of a transposase and a Mu like integrase, two proteins essential for the insertion of bacteriophage DNA into the bacterial chromosome.

DNA integration is a critical step for temperate bacteriophages. Rather than immediately destroying their host, these viruses may enter a latent state in which their genomes become part of the bacterial chromosome and replicate alongside it. This strategy enables phages to persist through unfavorable conditions and ensures their long term survival. The present study demonstrates that bacteriophages do not passively rely on host machinery to achieve this state. Instead, they actively manipulate bacterial signaling networks to increase the efficiency of genome integration.

The work also reveals an unexpected complexity in the regulation of this process. The prophage protein A1S_1154 interacts with a TetR family transcriptional regulator that normally represses genes involved in DNA integration. By interfering with the dimerization of this repressor, A1S_1154 relieves transcriptional inhibition and promotes the expression of integration machinery. This multilayered regulatory cascade illustrates how viruses exploit host regulatory circuits at several levels simultaneously.

Beyond its importance for Acinetobacter baumannii biology, this discovery expands our understanding of bacteriophage evolution and host manipulation. It demonstrates that cyclic nucleotide signaling, traditionally associated with bacterial physiology and immunity, can also be hijacked by viruses to support their own life cycle. Such mechanisms may be far more widespread than previously suspected and could exist in numerous bacterial species that harbor temperate bacteriophages.

These findings may also have implications for phage therapy. Therapeutic bacteriophages are generally selected according to their ability to eliminate bacterial pathogens. However, understanding how phages interact with intracellular signaling pathways may become equally important. Manipulating these signaling networks could influence phage persistence, genome integration and therapeutic efficacy, opening new avenues for designing more precise and effective phage based treatments.

As research continues to explore the molecular dialogue between bacteria and their viruses, it becomes increasingly clear that bacteriophages are not merely predators of microbial cells. They are highly sophisticated biological entities capable of reshaping the signaling architecture of their hosts, turning bacterial defense and regulatory pathways into powerful tools for their own survival.


Scientific source : https://www.science.org/doi/10.1126/sciadv.aec7770

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more